Nimotop

Nimotop

nimodipine

Manufacturer:

Bayer HealthCare Pharma

Distributor:

DKSH
Concise Prescribing Info
Contents
Nimodipine
Indications/Uses
Dosage/Direction for Use
Prevention & treatment of ischaemic neurological deficits due to cerebral vasospasm following subarachnoid haemorrhage Infusion of 1-2 mg/hr for 7-14 days then 2 tab 6 times daily for a further 7 days. Total duration of treatment: 21 days. Treatment of neurological deficits following an acute ischaemic brain infarction 1 tab qid. Treatment of impaired brain function in old age 1 tab tid.
Administration
May be taken with or without food: Swallow whole, do not chew/crush. Take consistently, either always w/ or w/o meals.
Special Precautions
Generalized cerebral edema or severely raised intracranial pressure; renal or liver impairment; pregnancy.
Adverse Reactions
Severe BP lowering. GI disturbances. In addition for infusion: Deterioration of renal function, disturbances of heart rhythm, phlebitis, increase of liver enzymes.
Drug Interactions
Potentiates effects of antihypertensives. Avoid IV β-blockers. Possible increase of nimodipine blood conc w/ cimetidine. Possible decrease of nimodipine efficacy w/ rifampicin. Infusion: Ca antagonists, methyldopa. Nephrotoxic drugs, monitor renal function.
ATC Classification
C08CA06 - nimodipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Presentation/Packing
Form
Nimotop film-coated tab 30 mg
Packing/Price
30's
Form
Nimotop infusion 10 mg/50 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in